A single and multiple ascending dose study to investigate safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD2389 in healthy participants

Exclusion Criteria

• • Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IMP.
• • Known or suspected history of alcohol or drug abuse and smokers.
• • Plasma donation within one month of the Screening Visit or any blood donation/blood loss > 500 mL during the 3 months prior to the Screening Visit.
• • History of coagulation or bleeding disorders or use of anti-platelets/anti-coagulants during the 3 months prior to the Screening Visit, as judged by the investigator.
• • History of hypersensitivity as judged by the investigator, to drugs with a similar chemical structure or class.
• • History of severe dermatological disorders, eg, bullous pemphigoid or Stevens-Johnson syndrome, or clinically significant new or healing wounds in areas of the body not always covered by clothing such as face, forearm, and lower leg, as judged by the investigator.